Please assess the completion status of the following clinical trial:

Trial Title: Pessary Versus Cerclage With or Without Progesterone in Twins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women with a twin pregnancy (mono- and di-chorionic)~* 16 0/7 to 22 0/7 weeks of gestation~* Maternal age ≥18 yrs~* Cervical length ≤28 mm~* Informed consent~* Not participating in another preterm birth study at the same time~Exclusion Criteria:~* Uterine anomalies~* Cervical dilation with visible amniotic membranes or amniotic membranes prolapsed into the vagina~* Twin-to-twin transfusion syndrome~* Stillbirth or major congenital abnormalities in any of the fetus~* Severe vaginal discharge~* Acute vaginitis or cervicitis~* Vaginal bleeding~* Placental preavia~* Vasa preavia~* Premature rupture of membranes~* Premature labor with/without ruptured membrane~* Suspicion of chorioamnionitis~* Cerclage or pessary in place or unable to undergo cervical cerclage or pessary

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pessary group (Type: ACTIVE_COMPARATOR): A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
- Cerclage group (Type: ACTIVE_COMPARATOR): Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
- Pessary plus progesterone group (Type: ACTIVE_COMPARATOR): 400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
- Cerclage plus progesterone group (Type: ACTIVE_COMPARATOR): 400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).